Home » Newsletters » The Carlat Addiction Treatment Report

The Carlat Addiction Treatment Report

Dual Diagnosis in Addiction Medicine (May/June) | 2019

View Archived Issues

CME Post-Test - Dual Diagnosis in Addiction Medicine, CATR, May/June 2019

May 21, 2019

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 2 CME credits. Read More

Managing Substance-Related Agitation

May 21, 2019

Thomas Jordan, MD, MPH

In emergency departments, psychiatrists are often consulted on patients presenting with agitation. In many cases, these patients are under the influence of substances—either from intoxication or withdrawal. Read More

Treating Co-Occurring Psychiatric Disorders

May 21, 2019

Stephen Ross, MD

Just about any psychiatric disorder has a higher rate of addiction comorbidity than in the general population. The rates are even higher in treatment settings—more than 50% of people in addiction treatment settings will have a co-occurring psychiatric problem, and more than 50% in psychiatric settings will typically have a co-occurring Substance Use Disorder. Read More

Cognitive Behavioral Therapy for Substance Use Disorders

May 21, 2019

Here’s the basic framework of Cognitive Behavioral Therapy (CBT), how it can be applied to Substance Use Disorders, and ways to incorporate parts of CBT into your daily addiction treatment practice. Read More

Co-Occurring Addiction and PTSD

May 21, 2019

Dolores Vojvoda, MD

Individuals who have PTSD have a high risk of developing other disorders, including substance use disorders (SUDs). Studies have shown that both in the veteran and non-veteran populations, these numbers are high. Read More

Oral vs Extended-Release Naltrexone for Opioid Use Disorder

May 21, 2019

Jessica Goren, PharmD.

Extended-release (XR) naltrexone (Vivitrol) is FDA approved for opioid use disorder and has shown efficacy in several trials. It works best for patients who have already successfully detoxed from opioids and who are highly motivated to abstain. But what about oral naltrexone? Read More

Does Extended-Release Naltrexone Worsen Psychiatric Symptoms?

May 21, 2019

Brian Frankel, MD.

Extended-release (XR) naltrexone (Vivitrol) is an injectable version of naltrexone that lasts for 4 weeks and is FDA approved for opioid use disorder (OUD). Although effective, there is some concern that XR naltrexone may cause or worsen psychiatric symptoms because of its opioid blockade. Read More